SG11201808220VA - Allosteric modulators of nicotinic acetylcholine receptors - Google Patents
Allosteric modulators of nicotinic acetylcholine receptorsInfo
- Publication number
- SG11201808220VA SG11201808220VA SG11201808220VA SG11201808220VA SG11201808220VA SG 11201808220V A SG11201808220V A SG 11201808220VA SG 11201808220V A SG11201808220V A SG 11201808220VA SG 11201808220V A SG11201808220V A SG 11201808220VA SG 11201808220V A SG11201808220V A SG 11201808220VA
- Authority
- SG
- Singapore
- Prior art keywords
- pike
- pennsylvania
- sumneytown
- west point
- international
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Control Of El Displays (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD 1111101110101011111 HO 11111 011101111011110101111101111111011011# International Bureau ... ...j .......,./ (10) International Publication Number (43) International Publication Date WO 2017/165256 Al 28 September 2017 (28.09.2017) WIP0 I PCT (51) International Patent Classification: Ranley Grove, Paddington, New South Wales QLD4064 C07D 231/12 (2006.01) C07D 261/08 (2006.01) C07D 233/64 (2006.01) C07D 263/32 (2006.01) C07D 413/04 (2006.01) C07D 271/06 (2006.01) C07D 413/06 (2006.01) C07D 495/04 (2006.01) (AU). HUFF, Belinda, C. [AU/AU]; 85 Morphett Road, Camden Park, South Australia 5038 (AU). LEAVITT, Kenneth, J. [US/US]; 770 Sumneytown Pike, West Point, Pennsylvania 19486 (US). RADA, Vanessa, L. [US/US]; C07D 413/10 (2006.01) C07D 277/26 (2006.01) 770 Sumneytown Pike, West Point, Pennsylvania 19486 C07D 417/04 (2006.01) C07D 285/08 (2006.01) (US). SANDERS, John, M. [US/US]; 770 Sumneytown C07D 249/06 (2006.01) CO7D 285/12 (2006.01) Pike, West Point, Pennsylvania 19486 (US). SHIPE, Wil- CO7D 249/08 (2006.01) Ram, D. [US/US]; 770 Sumneytown Pike, West Point, (21) International Application Number: Pennsylvania 19486 (US). SUEN, Linda, M. [US/US]; PCT/US2017/023127 770 Sumneytown Pike, West Point, Pennsylvania 19486 (US). BELL, Ian, M. [US/US]; 770 Sumneytown Pike, (22) International Filing Date: West Point, Pennsylvania 19486 (US). 20 March 2017 (20.03.2017) (74) Common Representative: MERCK SHARP & DOHME (25) Filing Language: English CORP.; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 62/311,888 22 March 2016 (22.03.2016) US AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 62/369,778 2 August 2016 (02.08.2016) US BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (71) Applicant: MERCK SHARP & DOHME CORP. DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 07065-0907 (US). KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, = Inventors; and NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (72) (71) Applicants (for US only): CROWLEY, Brendan, M. RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, [US/US]; 770 Sumneytown Pike, West Point, Pennsylvania TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, 19486 (US). CAMPBELL, Brian, T. [US/US]; 770 Sum- ZA, ZM, ZW. neytown Pike, West Point, Pennsylvania 19486 (US). DUFFY, Joseph, L. [US/US]; 2000 Galloping Hill Road, (84) Designated States (unless otherwise indicated, for every Kenilworth, New Jersey 07033 (US). GRESHOCK, kind of regional protection available): ARIPO (BW, GH, Thomas, J. [US/US]; 770 Sumneytown Pike, West Point, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Pennsylvania 19486 (US). GUIADEEN, Deodial, G. TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, [US/US]; 770 Sumneytown Pike, West Point, Pennsylvania TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 19486 (US). HARVEY, Andrew John [AU/AU]; 4A/6 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, [Continued on next page] Title: ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS (54) R 3 R4 Y \ A ir) ei R 5 ir) X 0) 1-1 N 1-1 (57) : The present disclosure relates to compounds of formula (I) that are useful as modulators of ca nAChR, compositions N comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well 0 as for L-DOPA induced-dyskinesia and inflammation. WO 2017/165256 Al MIDEDIMOMOIDEIR010130HinillUMMOIMIE SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, as to the applicant's entitlement to claim the priority of GW, KM, ML, MR, NE, SN, TD, TG). the earlier application (Rule 4.17(iii)) Declarations under Rule 4.17: Published: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(0 with international search report (Art. 21(3))
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662311888P | 2016-03-22 | 2016-03-22 | |
US201662369778P | 2016-08-02 | 2016-08-02 | |
PCT/US2017/023127 WO2017165256A1 (en) | 2016-03-22 | 2017-03-20 | Allosteric modulators of nicotinic acetylcholine receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201808220VA true SG11201808220VA (en) | 2018-10-30 |
Family
ID=58455680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201808220VA SG11201808220VA (en) | 2016-03-22 | 2017-03-20 | Allosteric modulators of nicotinic acetylcholine receptors |
Country Status (39)
Country | Link |
---|---|
US (3) | US9840481B2 (en) |
EP (2) | EP3978479A1 (en) |
JP (1) | JP6526352B2 (en) |
KR (1) | KR102203552B1 (en) |
CN (1) | CN109153649B (en) |
AR (1) | AR107928A1 (en) |
AU (1) | AU2017237930B2 (en) |
CA (1) | CA3018185C (en) |
CL (1) | CL2018002697A1 (en) |
CO (1) | CO2018009889A2 (en) |
CR (1) | CR20180452A (en) |
CY (1) | CY1124828T1 (en) |
DK (1) | DK3433234T3 (en) |
DO (1) | DOP2018000204A (en) |
EC (1) | ECSP18078877A (en) |
ES (1) | ES2901197T3 (en) |
GE (1) | GEP20207149B (en) |
HR (1) | HRP20211960T1 (en) |
HU (1) | HUE057460T2 (en) |
IL (1) | IL261807A (en) |
JO (1) | JOP20170067B1 (en) |
LT (1) | LT3433234T (en) |
MA (1) | MA43756B1 (en) |
MD (1) | MD3433234T2 (en) |
MX (1) | MX2018011453A (en) |
MY (1) | MY195948A (en) |
PE (1) | PE20181851A1 (en) |
PH (1) | PH12018502028A1 (en) |
PL (1) | PL3433234T3 (en) |
PT (1) | PT3433234T (en) |
RS (1) | RS62704B1 (en) |
SG (1) | SG11201808220VA (en) |
SI (1) | SI3433234T1 (en) |
SV (1) | SV2018005743A (en) |
TN (1) | TN2018000322A1 (en) |
TW (1) | TWI616438B (en) |
UA (1) | UA120571C2 (en) |
WO (1) | WO2017165256A1 (en) |
ZA (1) | ZA201806141B (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016168056A1 (en) | 2015-04-17 | 2016-10-20 | Dow Agrosciences Llc | Molecules having pesticidal utility, and intermediates, composition, and processes, related thereto |
US10258045B2 (en) | 2016-10-12 | 2019-04-16 | Dow Agrosciences Llc | Molecules having pesticidal utility and intermediates, compositions and processes related thereto |
EP3534888B1 (en) * | 2016-11-01 | 2022-04-06 | Merck Sharp & Dohme Corp. | Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors |
US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
WO2019000238A1 (en) * | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5-(pyridin-3-yl)oxazole allosteric modulators of m4 muscarinic acetylcholine receptor |
US11198687B2 (en) | 2017-09-19 | 2021-12-14 | Merck Sharp & Dohme Corp. | Heteroaryl allosteric modulators of nicotinic acetylcholine receptors |
SG11202010459XA (en) | 2018-05-01 | 2020-11-27 | Merck Sharp & Dohme | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors |
HU231478B1 (en) | 2018-07-13 | 2024-02-28 | Richter Gedeon Nyrt. | Substituted (aza)indole derivatives |
HU231414B1 (en) * | 2018-07-13 | 2023-08-28 | Richter Gedeon Nyrt. | Thiadiazine derivatives |
HU231333B1 (en) * | 2018-07-13 | 2023-01-28 | Richter Gedeon Nyrt | Spirochromane derivatives |
TW202039420A (en) * | 2018-11-26 | 2020-11-01 | 美商富曼西公司 | Meta-diamide compounds for controlling invertebrate pests |
WO2020223136A1 (en) * | 2019-05-02 | 2020-11-05 | Merck Sharp & Dohme Corp. | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors |
WO2021091751A1 (en) * | 2019-11-05 | 2021-05-14 | Merck Sharp & Dohme Corp. | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors |
CN111233783B (en) * | 2020-03-13 | 2021-11-16 | 温州大学 | Synthetic method of isothiazol-4-yl disulfide derivative |
WO2023049058A1 (en) * | 2021-09-21 | 2023-03-30 | Merck Sharp & Dohme Llc | Allosteric modulators of nicotinic acetylcholine receptors |
CA3235444A1 (en) * | 2021-10-12 | 2023-04-20 | Brown University | Glioblastoma multiforme treatments |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3487154A (en) | 1967-04-03 | 1969-12-30 | Smithkline Corp | Method of lowering blood pressure |
US3522302A (en) | 1967-05-16 | 1970-07-28 | Smithkline Corp | P-(2-aminocycloalkyl)benzenesulfonamides |
FR2508033A1 (en) | 1981-06-23 | 1982-12-24 | Fabre Sa Pierre | ARYL-1 AMINOMETHYL-2 CYCLOPROPANES CARBOXYLATES (Z), THEIR PREPARATION AND THEIR USE AS MEDICAMENTS USEFUL IN THE TREATMENT OF VARIOUS ALGAE |
US5286736A (en) | 1990-11-22 | 1994-02-15 | Dr. Karl Thomae Gmbh | Pyridyl compounds and pharmaceutical compositions containing these compounds |
TW394761B (en) | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
FR2751645B1 (en) | 1996-07-29 | 1998-12-24 | Sanofi Sa | AMINES FOR THE MANUFACTURE OF DRUGS TO PREVENT THE PROLIFERATION OF TUMOR CELLS |
AR017014A1 (en) | 1997-07-22 | 2001-08-22 | Astrazeneca Ab | TRIAZOL COMPOUNDS [4,5-D] PYRIMIDINE, PHARMACEUTICAL COMPOSITIONS, USE OF THE SAME TO PREPARE MEDICATIONS AND PROCESSES FOR THE PREPARATION OF SUCH COMPOUNDS |
CN1291193A (en) | 1998-02-17 | 2001-04-11 | 阿斯特拉曾尼卡英国有限公司 | Novel triazolo (4.5-d) pyrimidine compounds |
SE9802574D0 (en) | 1998-07-17 | 1998-07-17 | Astra Pharma Prod | Novel compounds |
US6887870B1 (en) | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
JP2003523356A (en) | 2000-01-29 | 2003-08-05 | エルジー シーアイ リミテッド | Factor Xa inhibitors with aryl-amidines, their derivatives, and their prodrugs |
US6630469B2 (en) | 2000-05-09 | 2003-10-07 | Bristol-Myers Squibb Company | 5-HT7 receptor antagonists |
FR2810664B1 (en) * | 2000-06-27 | 2004-12-24 | Adir | NOVEL CYCLOPROPANE COMPOUNDS, 1,1 AND 1,2-DISSUBSTITUES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
HUP0400343A2 (en) | 2001-03-29 | 2004-09-28 | Bristol-Myers Squibb Co. | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors, process for their preparation and pharmaceutical compositions containing them |
CA2479618A1 (en) | 2002-03-26 | 2003-10-09 | William K. Hagmann | Spirocyclic amides as cannabinoid receptor modulators |
ATE506354T1 (en) | 2003-01-06 | 2011-05-15 | Lilly Co Eli | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDE AS GLUCOCINASE ACTIVATORS |
EP1833804A1 (en) * | 2004-12-28 | 2007-09-19 | AstraZeneca AB | Aryl sulphonamide modulators |
WO2007025089A2 (en) * | 2005-08-24 | 2007-03-01 | Rib-X Pharmaceutical, Inc. | Triazole compounds and methods of making and using the same |
CN102058571B (en) | 2005-09-09 | 2012-09-19 | 有限会社肯菲思 | Use of 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2- naphthalenyl)carbamoyl]benzoic acid in preparing a pharmaceutical for use in prevention and/or treatment of bowel adhesion |
ES2460897T3 (en) | 2007-10-04 | 2014-05-14 | F. Hoffmann-La Roche Ag | Cyclopropyl aryl amide derivatives and uses thereof |
CA2707789A1 (en) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Phenyl acetic acid derivatives as inflammation modulators |
CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
ATE556998T1 (en) | 2008-08-12 | 2012-05-15 | Hoffmann La Roche | SALICYLAMIDE DERIVATIVES AS NICOTINIC ALPHA-7 MODULATORS |
PE20120061A1 (en) | 2008-12-19 | 2012-02-19 | Boehringer Ingelheim Int | PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR2 RECEPTOR |
WO2010084160A1 (en) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
SG171708A1 (en) | 2009-06-11 | 2011-07-28 | Abbott Lab | Anti-viral compounds to treat hcv infection |
WO2010144959A1 (en) | 2009-06-18 | 2010-12-23 | Fibrotech Therapeutics Pty Ltd | Analogues of anti-fibrotic agents |
US8552022B2 (en) * | 2009-08-13 | 2013-10-08 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
WO2012012410A2 (en) | 2010-07-19 | 2012-01-26 | Dr. Reddy's Laboratories Ltd. | Kappa opioid receptor agonists |
US20120108500A1 (en) | 2010-10-07 | 2012-05-03 | Naoki Sakane | Compositions and Methods for Modulating Immunodeficiency Virus Transcription |
CN103354808B (en) | 2010-12-16 | 2016-08-10 | Abbvie公司 | Antiviral compound |
KR101925971B1 (en) | 2011-01-28 | 2018-12-06 | 에스케이바이오팜 주식회사 | Pharmaceutical composition comprising pyridone derivatives |
US9062013B2 (en) | 2011-02-02 | 2015-06-23 | Bionomics Limited | Positive allosteric modulators of the α7 nicotinic acetylcholine receptor and uses thereof |
ES2594409T3 (en) | 2011-02-23 | 2016-12-20 | Lupin Limited | Heteroaryl derivatives as modulators of nAChR á7 |
WO2012151361A1 (en) | 2011-05-03 | 2012-11-08 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
WO2013005153A1 (en) * | 2011-07-05 | 2013-01-10 | Lupin Limited | Biaryl derivatives as nachr modulators |
US8598213B2 (en) | 2011-07-08 | 2013-12-03 | H. Lundbeck A/S | Positive allosteric modulators of nicotinic acetylcholine receptor |
UA111746C2 (en) * | 2011-07-08 | 2016-06-10 | Х. Луннбек А/С | POSITIVE Allosteric Modulators of the Nicotinic Acetylcholine Receptor |
ES2609003T3 (en) | 2011-08-08 | 2017-04-18 | Merck Patent Gmbh | N- (benzimimazol-2-yl) -cyclopropane carboxamides as lysophosphatidic acid antagonists |
WO2014006120A1 (en) | 2012-07-06 | 2014-01-09 | H. Lundbeck A/S | New positive allosteric modulators of nicotinic acetylcholine receptor |
RU2015106915A (en) * | 2012-08-01 | 2016-09-20 | Мерк Шарп И Доум Корп. | Α7 NICOTINE ACETYLCHOLINE RECEPTOR MODULATORS AND THEIR APPLICATION |
WO2014090731A1 (en) | 2012-12-10 | 2014-06-19 | H. Lundbeck A/S | New positive allosteric modulators of nicotinic acetylcholine receptor |
PL2968440T3 (en) | 2013-03-15 | 2019-12-31 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US9593096B2 (en) | 2013-04-24 | 2017-03-14 | Merck Sharp & Dohme Corp. | α7 nicotinic acetylcholine receptor modulators and uses thereof-III |
TW201446243A (en) | 2013-06-03 | 2014-12-16 | Lupin Ltd | 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1H-pyrrol-3-yl)benzenesulfonamide as alpha 7 nAChR modulator |
EP3086815B1 (en) | 2013-12-27 | 2022-02-09 | Zymeworks Inc. | Sulfonamide-containing linkage systems for drug conjugates |
US10675355B2 (en) | 2013-12-27 | 2020-06-09 | Var2 Pharmaceuticals Aps | VAR2CSA-drug conjugates |
JP6635949B2 (en) | 2014-06-04 | 2020-01-29 | トーマス・ヘレデイズ・スティフテルス・フォー・メディシンスク・フォルスクニング | MTH1 inhibitors for the treatment of inflammatory and autoimmune diseases |
CA2949785A1 (en) | 2014-06-04 | 2015-12-10 | Thomas Helledays Stiftelse For Medicinsk Forskning | Mth1 inhibitors for treatment of cancer |
WO2015191799A1 (en) * | 2014-06-13 | 2015-12-17 | Merck Sharp & Dohme Corp. | Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof |
-
2017
- 2017-03-20 GE GEAP201714908A patent/GEP20207149B/en unknown
- 2017-03-20 MY MYPI2018001607A patent/MY195948A/en unknown
- 2017-03-20 AU AU2017237930A patent/AU2017237930B2/en active Active
- 2017-03-20 CA CA3018185A patent/CA3018185C/en active Active
- 2017-03-20 US US15/463,336 patent/US9840481B2/en active Active
- 2017-03-20 CN CN201780031228.9A patent/CN109153649B/en active Active
- 2017-03-20 TN TNP/2018/000322A patent/TN2018000322A1/en unknown
- 2017-03-20 RS RS20211533A patent/RS62704B1/en unknown
- 2017-03-20 HU HUE17714623A patent/HUE057460T2/en unknown
- 2017-03-20 TW TW106109075A patent/TWI616438B/en active
- 2017-03-20 US US16/087,382 patent/US20190337910A1/en not_active Abandoned
- 2017-03-20 MD MDE20190130T patent/MD3433234T2/en unknown
- 2017-03-20 WO PCT/US2017/023127 patent/WO2017165256A1/en active Application Filing
- 2017-03-20 KR KR1020187029892A patent/KR102203552B1/en active IP Right Grant
- 2017-03-20 EP EP21204099.2A patent/EP3978479A1/en not_active Withdrawn
- 2017-03-20 HR HRP20211960TT patent/HRP20211960T1/en unknown
- 2017-03-20 ES ES17714623T patent/ES2901197T3/en active Active
- 2017-03-20 CR CR20180452A patent/CR20180452A/en unknown
- 2017-03-20 SI SI201730988T patent/SI3433234T1/en unknown
- 2017-03-20 DK DK17714623.0T patent/DK3433234T3/en active
- 2017-03-20 AR ARP170100686A patent/AR107928A1/en unknown
- 2017-03-20 JP JP2018549170A patent/JP6526352B2/en active Active
- 2017-03-20 MX MX2018011453A patent/MX2018011453A/en active IP Right Grant
- 2017-03-20 PL PL17714623T patent/PL3433234T3/en unknown
- 2017-03-20 PT PT177146230T patent/PT3433234T/en unknown
- 2017-03-20 UA UAA201809635A patent/UA120571C2/en unknown
- 2017-03-20 JO JOP/2017/0067A patent/JOP20170067B1/en active
- 2017-03-20 LT LTEPPCT/US2017/023127T patent/LT3433234T/en unknown
- 2017-03-20 PE PE2018001841A patent/PE20181851A1/en unknown
- 2017-03-20 EP EP17714623.0A patent/EP3433234B1/en active Active
- 2017-03-20 SG SG11201808220VA patent/SG11201808220VA/en unknown
- 2017-03-20 MA MA43756A patent/MA43756B1/en unknown
- 2017-10-09 US US15/727,982 patent/US9926285B2/en active Active
-
2018
- 2018-09-13 ZA ZA2018/06141A patent/ZA201806141B/en unknown
- 2018-09-16 IL IL261807A patent/IL261807A/en active IP Right Grant
- 2018-09-19 SV SV2018005743A patent/SV2018005743A/en unknown
- 2018-09-19 CO CONC2018/0009889A patent/CO2018009889A2/en unknown
- 2018-09-21 DO DO2018000204A patent/DOP2018000204A/en unknown
- 2018-09-21 CL CL2018002697A patent/CL2018002697A1/en unknown
- 2018-09-21 PH PH12018502028A patent/PH12018502028A1/en unknown
- 2018-10-19 EC ECSENADI201878877A patent/ECSP18078877A/en unknown
-
2021
- 2021-12-16 CY CY20211101106T patent/CY1124828T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201808220VA (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
SG11201804936UA (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
SG11201408186TA (en) | Pyridinone and pyridazinone derivatives | |
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201808354PA (en) | Column-based fully scalable raav manufacturing process | |
SG11201407988UA (en) | Process for improved opioid synthesis | |
SG11201901873PA (en) | Tablet compositions | |
SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
SG11201809560QA (en) | Enhancer of zeste homolog 2 inhibitors | |
SG11201811671XA (en) | Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof | |
SG11201909807TA (en) | Methods of manufacturing of niraparib | |
SG11201810519XA (en) | A rinse composition, a method for forming resist patterns and a method for making semiconductor devices | |
SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF | |
SG11201407934UA (en) | Camsylate salt | |
SG11201901188VA (en) | Metal powder feedstocks for additive manufacturing, and system and methods for producing the same | |
SG11201806424TA (en) | Therapeutic compounds | |
SG11201803762RA (en) | High viscosity base stock compositions | |
SG11201805141QA (en) | Compositions and methods for detecting and treating gastric cancer | |
SG11201906666QA (en) | Methods of preparing cytotoxic benzodiazepine derivatives | |
SG11201810537RA (en) | Polymer composition, its process of preparation, its use and composition comprising it | |
SG11201809471UA (en) | Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof | |
SG11201806982PA (en) | Cinnolin-4-amine compounds and their use in treating cancer |